Clinical Trial

A Study of BGM0504 in Participants with Type 2 Diabetes

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated March 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-29; most recent amendment 2025-02-06.
Trial Details
NCT Number NCT06716216
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Collaborators: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 537 participants
Start Date 2024-11-29
Primary Completion 2026-03-20 (estimated)
Study Completion 2026-11-14 (estimated)
Updated on ClinicalTrials.gov 2025-02-07